Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36

Microbes and Infection

Volumn 3, Issue 9, 2001, Pages 701-711

  Gonzalo, Rosa María ^a   Rodríguez, Juan Ramón ^a   Rodríguez, Dolores ^a   González Aseguinolaza, Gloria ^b   Larraga, Vicente ^b   Esteban, Mariano ^a  

^a CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^b CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

Cytokines; Leishmaniasis; Rodent; Vaccination

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 10; PROTEIN; RECOMBINANT INTERLEUKIN 12; RECOMBINANT VACCINE; VACCINIA VACCINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; KIDNEY CELL; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LYMPHOCYTE ACTIVATION; MONKEY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; PROTEIN EXPRESSION; SKIN LEISHMANIASIS; TH1 CELL;

ANIMALIA; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; RODENTIA; VACCINIA; VACCINIA VIRUS;

EID: 0034910319     PISSN: 12864579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1286-4579(01)01426-5     Document Type: Article

References (52)

1. Control of leishmaniasis
2. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis
3. Immunology of leishmaniasis
4. Cellular and humoral immune responses in dogs experimentally and naturally infected with Leishmania infantum
5. Leishmania infantum-specific T cell lines derived from asymptomatic dogs that lyse infected macrophages in a major histocompatibility complex-restricted manner
6. An analysis of T cell responsiveness in Indian Kala-azar
7. Two types of mouse helper T cell clones I. Definition according to profiles of lymphokine activities and secrete proteins
8. Human Th1 and Th2 subsets: Doubt no more
9. Resolution of cutaneous leishmaniasis: Interleukin 12 initiates a protective T helper type 1 immune response
10. Interleukin 12: A proinflamatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
11. IL-12 is required to maintain a Th1 response during Leishmania major infection
12. Effective immunization against cutaneous leishmaniasis with defined membrane-antigens reconstituted into liposomes
13. Membrane glycoprotein M-2 protects against L. amazonensis infection
14. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis
15. Expression cloning of a protective Leishmania antigen
16. Protective immune responses induced by vaccination with an expression genomic library of Leishmania major
17. Recombinant Vaccinia viruses expressing GP46/M2 protect against Leishmania infection
18. Selective down-regulation of Th2 immune responses following treatment with antigen-coupled splenocytes
19. Resistance to Leishmania major induced by tolerance to a single antigen
20. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major
21. Applications of pox virus vectors to vaccination: An update
22. IL-12 delivery from recombinant Vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 env in a dose-dependent manner
23. Molecular cloning, cell localization and binding affinity to DNA replication proteins of the p36/LACK protective antigen from Leishmania infantum
24. Cloning, molecular analysis and differential cell localisation of the p36 RACK analogue antigen from the parasite protozoon Crithidia fasciculata
25. Early parasite containment is decisive for resistance to L. major infection
26. Compact, synthetic, Vaccinia virus early/late promoter for protein expression
27. E. coli beta-glucuronidase (GUS) as a marker for recombinant Vaccinia viruses
28. Isolation and characterization of attenuated mutants of Vaccinia virus
29. Mucosal IL-12 gene delivery inhibits allergic airways disease and restores local antiviral immunity
30. Culture microtitration: A sensitive method for quantifying Leishmania infantum in tissues of infected mice
31. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge
32. A striking property of Vaccinia viruses: Efficient inducers of in vivo expansion of primed CD8+ T cells
33. Lymphokine control of in vivo immunoglobulin isotype selection
34. Immunization of susceptible hosts with a soluble antigen fraction from L. major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells
35. + lymphocytes in vivo during healing and progressive murine leishmaniasis
36. Susceptibility to Leishmania major infection in interleukin-4 deficient mice
37. + T cell recognition
38. Cytokine-induced synthesis of nitrogen oxides in macrophages: A protective host response to Leishmania and other intracellular pathogens
39. Leishmania major amastigotes initiate the L-arginine-dependant killing mechanism in IFN-gamma-stimulated macrophages by induction of tumor necrosis factor-alpha
40. Designer vaccines for parasitic diseases
41. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major
42. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection
43. A single intramuscular injection with Adenovirus-expressing IL-12 protects Balb/c mice against Leishmania major infection, while treatment with IL-4-expressing vector increases disease susceptibility in B10D2 mice
44. IL-12 enhancement of the cellular immune response against HIV-1 Env antigen in a DNA prime/Vaccinia virus boost vaccine regimen is time and dose-dependent: Suppressive effects of IL-12 boost are mediated by nitric oxide
45. + T cells using heterologous prime-boost immunisation strategies
46. + T cell response to HIV-1 env by combined immunization with Influenza and Vaccinia virus recombinants
47. Boosting with recombinant Vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
48. + T cell responses in mice
49. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS
50. New prospects for the development of a vaccine against human immunodeficiency virus type 1. An overview